2022
Multiple Intravenous Bolus Dosing and Invasive Hemodynamic Assessment in a Hypoxia-Induced Mouse Pulmonary Artery Hypertension Model.
Qin L, Jiang B, Zsebo K, Duckers H, Simons M, Chen P. Multiple Intravenous Bolus Dosing and Invasive Hemodynamic Assessment in a Hypoxia-Induced Mouse Pulmonary Artery Hypertension Model. Journal Of Visualized Experiments 2022 PMID: 36440832, DOI: 10.3791/63839.Peer-Reviewed Original ResearchConceptsPulmonary arterial hypertensionInvasive hemodynamic assessmentHemodynamic assessmentPAH modelProgressive life-threatening diseaseGroup 3 diseaseRight ventricle catheterizationSmall pulmonary arteriolesIntravenous bolus dosingNew experimental therapiesLife-threatening diseaseAdministration of compoundsMouse jugular veinHuman clinical manifestationsArterial hypertensionHypertension modelPulmonary arteriolesClinical manifestationsBolus dosingExperimental therapiesIntravenous administrationJugular veinPAH researchMultiple injectionsTime coursePredictive factors and outcomes for ibrutinib in relapsed/refractory marginal zone lymphoma: a multicenter cohort study
Epperla N, Zhao Q, Chowdhury SM, Shea L, Moyo TK, Reddy N, Sheets J, Weiner DM, Geethakumari PR, Kandarpa M, Bruno XJ, Thomas C, Churnetski MC, Hsu A, Zurbriggen L, Tan C, Lindsey K, Maakaron J, Caimi PF, Torka P, Bello C, Ayyappan S, Karmali R, Kim SH, Kress A, Kothari S, Sawalha Y, Christian B, David KA, Greenwell IB, Janakiram M, Kenkre VP, Olszewski AJ, Cohen JB, Palmisiano N, Umyarova E, Wilcox RA, Awan FT, Alderuccio JP, Barta SK, Grover NS, Ghosh N, Bartlett NL, Herrera AF, Shouse G. Predictive factors and outcomes for ibrutinib in relapsed/refractory marginal zone lymphoma: a multicenter cohort study. Journal Of Hematology & Oncology 2022, 15: 96. PMID: 35842643, PMCID: PMC9287914, DOI: 10.1186/s13045-022-01316-1.Peer-Reviewed Original ResearchConceptsMarginal zone lymphomaRefractory marginal zone lymphomaMulticenter cohort studyPrimary refractory diseaseOverall response rateStable diseaseCohort studyComplex cytogeneticsRefractory diseaseFirst-line therapyHigh-risk subsetType of therapyProgression of diseaseInferior OSInferior PFSMedian PFSPartial responsePredictive factorsExperimental therapiesStudy populationEligibility criteriaClinical practicePatientsResponse rateIbrutinib
2021
Effective Therapy Targeting Cytochrome bc1 Prevents Babesia Erythrocytic Development and Protects from Lethal Infection
Chiu JE, Renard I, Pal AC, Singh P, Vydyam P, Thekkiniath J, Kumar M, Gihaz S, Pou S, Winter RW, Dodean R, Frueh L, Nilsen AC, Riscoe MK, Doggett JS, Mamoun C. Effective Therapy Targeting Cytochrome bc1 Prevents Babesia Erythrocytic Development and Protects from Lethal Infection. Antimicrobial Agents And Chemotherapy 2021, 65: 10.1128/aac.00662-21. PMID: 34152821, PMCID: PMC8370247, DOI: 10.1128/aac.00662-21.Peer-Reviewed Original ResearchConceptsEndochin-like quinolonesLethal infectionBlood-borne diseasesBlood-borne pathogensEffective therapyRelated apicomplexan parasitesExperimental therapiesLow doseMouse modelInfectious agentsHuman infectionsInfectionClinical candidatesStrong efficacyB. microtiExcellent safetyMode of actionTherapyErythrocytic developmentAtovaquoneEfficacyApicomplexan parasitesSafetyStructure-activity relationshipsParasitemiaDiffusion weighted imaging as a biomarker of retinoic acid induced myelomeningocele
Maassel N, Farrelly J, Coman D, Freedman-Weiss M, Ahle S, Ullrich S, Yung N, Hyder F, Stitelman D. Diffusion weighted imaging as a biomarker of retinoic acid induced myelomeningocele. PLOS ONE 2021, 16: e0253583. PMID: 34191842, PMCID: PMC8244849, DOI: 10.1371/journal.pone.0253583.Peer-Reviewed Original ResearchConceptsMagnetic resonance imaging techniquesSpinal cordRat fetusesRetinoic acidCommon congenital anomalyComplementary imaging biomarkerLack of skinNeural tube defectsTrans retinoic acidBony coveringRat damsCongenital anomaliesRat modelExperimental therapiesHistopathologic analysisSevere formBrain volumeMyelomeningoceleImaging biomarkersDisease severityMMC defectsTube defectsIncomplete closureFetusesFractional anisotropy (FA) mapsAdverse Effects Associated With the Use of Antimalarials During The COVID-19 Pandemic in a Tertiary Care Center in Mexico City
Lozano-Cruz O, Jiménez J, Olivas-Martinez A, Ortiz-Brizuela E, Cárdenas-Fragoso J, Azamar-Llamas D, Rodríguez-Rodríguez S, Oseguera-Moguel J, Dorantes-García J, Barrón-Magdaleno C, Cázares-Diazleal A, Román-Montes C, Tamez-Torres K, Martínez-Guerra B, Gulias-Herrero A, González-Lara M, Ponce-de-León-Garduño A, Kershenobich-Stalnikowitz D, Sifuentes-Osornio J. Adverse Effects Associated With the Use of Antimalarials During The COVID-19 Pandemic in a Tertiary Care Center in Mexico City. Frontiers In Pharmacology 2021, 12: 668678. PMID: 34149420, PMCID: PMC8210417, DOI: 10.3389/fphar.2021.668678.Peer-Reviewed Original ResearchAntimalarial drugsCOVID-19 pneumoniaAdverse effectsTreated with antimalarialsEffects of antimalarialsLiver function testsTertiary care centerGroup of patientsLowest oxygen saturationOptimal careRandomized Controlled TrialsOptimal medical careNo significant differenceImproved survivalBaseline characteristicsVentricular arrhythmiasAdult patientsRetrospective cohortAdverse eventsAntimalarialsExperimental therapiesHospitalized patientsSide effectsFunction testsHigher respiratory rate
2016
Detection of Therapeutically Targetable Driver and Resistance Mutations in Lung Cancer Patients by Next-Generation Sequencing of Cell-Free Circulating Tumor DNA
Thompson J, Yee S, Troxel A, Savitch S, Fan R, Balli D, Lieberman D, Morrissette J, Evans T, Bauml J, Aggarwal C, Kosteva J, Alley E, Ciunci C, Cohen R, Bagley S, Stonehouse-Lee S, Sherry V, Gilbert E, Langer C, Vachani A, Carpenter E. Detection of Therapeutically Targetable Driver and Resistance Mutations in Lung Cancer Patients by Next-Generation Sequencing of Cell-Free Circulating Tumor DNA. Clinical Cancer Research 2016, 22: 5772-5782. PMID: 27601595, PMCID: PMC5448134, DOI: 10.1158/1078-0432.ccr-16-1231.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerCtDNA next-generation sequencingResistance mutationsNext-generation sequencingTissue sequencingAdvanced non-small cell lung cancerActionable EGFR mutationsCell lung cancerProgressive diseaseConsecutive patientsCtDNA sequencingTargetable driversLung cancerClinical trialsDisease progressionEGFR mutationsUltra-deep sequencingPatient managementExperimental therapiesTumor genotypingCtDNA samplesTissue biopsiesPatientsAccurate diagnosisBlood collection
2013
Preclinical and Clinical Studies of Gamma Secretase Inhibitors with Docetaxel on Human Breast Tumors
Schott AF, Landis MD, Dontu G, Griffith KA, Layman RM, Krop I, Paskett LA, Wong H, Dobrolecki LE, Lewis MT, Froehlich AM, Paranilam J, Hayes DF, Wicha MS, Chang JC. Preclinical and Clinical Studies of Gamma Secretase Inhibitors with Docetaxel on Human Breast Tumors. Clinical Cancer Research 2013, 19: 1512-1524. PMID: 23340294, PMCID: PMC3602220, DOI: 10.1158/1078-0432.ccr-11-3326.Peer-Reviewed Original ResearchConceptsBreast cancer stem cellsGamma-secretase inhibitorsAdvanced breast cancerClinical trialsBreast cancerSecretase inhibitorsMaximum-tolerated doseEfficacy of docetaxelSerial tumor biopsiesNotch pathwayTumors of patientsDoses of MKConcurrent clinical trialsHuman breast tumorsNotch pathway inhibitorsCancer stem cellsManageable toxicityTumorgraft modelsDocetaxel treatmentBCSC markersSerial biopsiesConventional therapyPreclinical dataClinical studiesExperimental therapies
2006
Use of experimental therapy outside of clinical trials among U.S. oncologists
Peppercorn J, Joffe S, Burstein H, Winer E. Use of experimental therapy outside of clinical trials among U.S. oncologists. Journal Of Clinical Oncology 2006, 24: 6047-6047. DOI: 10.1200/jco.2006.24.18_suppl.6047.Peer-Reviewed Original ResearchClinical trialsPractice settingsInvestigational cancer therapiesAttitudes of physiciansDemographic factorsU.S. oncologistsCommunity oncologistsMedical oncologistsTrial enrollmentAcademic oncologistsRecent trialsExperimental therapiesPatient's requestAmerican oncologistsOncology communityGuideline developmentOncologistsPatientsSignificant financial relationshipTrialsMonthsCancer therapyTherapyRandom sampleCare
2005
Effect of combined treatment with methylprednisolone and soluble Nogo‐66 receptor after rat spinal cord injury
Ji B, Li M, Budel S, Pepinsky RB, Walus L, Engber TM, Strittmatter SM, Relton JK. Effect of combined treatment with methylprednisolone and soluble Nogo‐66 receptor after rat spinal cord injury. European Journal Of Neuroscience 2005, 22: 587-594. PMID: 16101740, PMCID: PMC2846292, DOI: 10.1111/j.1460-9568.2005.04241.x.Peer-Reviewed Original ResearchMeSH KeywordsAnalysis of VarianceAnimalsAxonsBehavior, AnimalBiotinCells, CulturedChick EmbryoDextransDisease Models, AnimalDose-Response Relationship, DrugDrug InteractionsDrug Therapy, CombinationExploratory BehaviorFemaleGanglia, SpinalGPI-Linked ProteinsImmunoglobulin GLaminectomyMethylprednisoloneMyelin ProteinsMyelin SheathNerve RegenerationNeuronsNogo Receptor 1Pyramidal TractsRatsRats, Long-EvansReceptors, Cell SurfaceReceptors, PeptideRecombinant ProteinsRecovery of FunctionSpinal Cord InjuriesConceptsSpinal cord injuryCord injuryRat spinal cord injuryMP treatmentAdult central nervous systemThoracic dorsal hemisectionNovel experimental therapiesCorticospinal tract axonsRecovery of functionNogo-66 receptorNumber of axonsCentral nervous systemGrowth inhibitory effectsDorsal hemisectionBBB scoresAxonal sproutingFunctional recoveryBresnahan (BBB) scoringAxonal regenerationMotor neuronsExperimental therapiesMethylprednisoloneSynthetic glucocorticoidNervous systemAxonal growth
1996
Gene Therapy in the United States: A Five-Year Status Report
Ross G, Erickson R, Knorr D, Motulsky A, Parkman R, Samulski J, Straus S, Smith B. Gene Therapy in the United States: A Five-Year Status Report. Human Gene Therapy 1996, 7: 1781-1790. PMID: 8886849, DOI: 10.1089/hum.1996.7.14-1781.Peer-Reviewed Original ResearchConceptsInstitutional review boardLocal institutional review boardFDA approvalHuman gene transfer trialsPhase I/IIGene transfer studiesPhase II studyPhase III studyRecruitment of patientsGene therapyYears of ageGene transfer trialsFinal FDA approvalII studyIII studyTotal patientsMedian timeFirst patientAnatomic distributionExperimental therapiesUnexpected toxicitiesNineteen studiesPatientsAutopsy rateAcademic centers
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply